First Trust Advisors LP Purchases Shares of 22,144 Fresenius Medical Care AG (NYSE:FMS)

First Trust Advisors LP acquired a new position in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,144 shares of the company's stock, valued at approximately $501,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Smartleaf Asset Management LLC increased its holdings in Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock worth $28,000 after purchasing an additional 806 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Fresenius Medical Care during the third quarter worth about $38,000. Russell Investments Group Ltd. raised its position in Fresenius Medical Care by 234.1% in the 4th quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company's stock valued at $71,000 after buying an additional 2,208 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in Fresenius Medical Care by 80.5% in the 4th quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company's stock valued at $102,000 after acquiring an additional 2,012 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its position in Fresenius Medical Care by 8.4% during the 4th quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company's stock worth $129,000 after acquiring an additional 441 shares during the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care Stock Up 1.9%

Shares of NYSE:FMS traded up $0.54 during trading on Thursday, hitting $28.39. 281,414 shares of the company were exchanged, compared to its average volume of 323,036. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $28.59. The stock has a market cap of $16.66 billion, a price-to-earnings ratio of 23.43, a P/E/G ratio of 0.76 and a beta of 0.85. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The firm has a fifty day moving average price of $24.80 and a two-hundred day moving average price of $23.56.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.01. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The firm had revenue of $5.54 billion for the quarter, compared to analyst estimates of $4.71 billion. As a group, research analysts anticipate that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be issued a dividend of $0.7871 per share. The ex-dividend date of this dividend is Friday, May 23rd. This represents a yield of 1.9%. This is a boost from Fresenius Medical Care's previous annual dividend of $0.44. Fresenius Medical Care's dividend payout ratio (DPR) is presently 49.11%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Truist Financial lifted their price objective on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the company a "hold" rating in a report on Monday. StockNews.com upgraded shares of Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.